Marketresearchnews

Tuesday, 12 February 2019

Microbiology Testing Market 2018 Market Challenge, Driver, Trends & Forecast to 2023

Market Scenario

The study of microbial germs and their clinical applications for the improvement of health is defined as microbiology testing. Market Research Future (MRFR) has published and released a research report on the global microbiology testing market that estimates massive enlargement for this market at 12.1% CAGR (Compound Annual Growth Rate) between 2017 and 2023. With regards to value, the market has been anticipated to be worth the US $ 5409.1 mn by the end of forecast period.

Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/697

The key factor supporting the global microbiology testing market growth is the increasing prevalence of various infectious diseases. The global microbiology testing market has been segmented into application, end user, product type, and lastly, region. The application-based segmentation of this market comprises of gastrointestinal infections, respiratory infections, sexually transmitted infections, urinary tract infections, and others.

On the basis of end users, the market has been segmented into academics & research institutes, hospital-based laboratory, and independent laboratory. Based on product type, the market has been segmented into chemicals & reagents, consumables & accessories, instruments, and others.

The regional segmentation of the global microbiology testing market can segment the global market into regional markets by the names of Asia Pacific, North America, Europe, and the Middle East & Africa (MEA). In 2016, North America held the largest share market in the global market which was 37.9%. During the forecast period, North America is expected to continue as the largest regional market because the advanced medical facilities are available in this region and support from government regarding investment on the research & development (R&D) is available. The indispensable country-specific markets in this region are USA and Canada. Many key market players are based in North America, especially in the USA.

In 2016, Europe was the second largest microbiology testing market. During the forecast period, there are expectations regarding steady and positive market growth. However, Europe may not retain its spot by the end of forecast period. European government support R&D investment in the medical sector and in terms of technological advancement in the medical sector, Europe is second only to North America. This makes Europe an important regional market. The most significant country-specific markets in this region are France, Germany, Italy, Spain, and the UK, followed by the remaining countries of Europe.

Right now, Asia Pacific is the second largest and fastest growing market in the global microbiology testing market this is to continue till the end of forecast period. This market is expected to grow at 12.1% CAGR between 2017 and 2023. The priority country-specific markets in this region are Australia, China, India, South Korea, and Japan, followed by the remaining countries of the Asia Pacific region.

The MEA region has the least market share due to poor countries, lack of awareness, lack of education, low standard of medical facilities, lack of advanced technology, lack of healthcare facilities, and majority governments not considering healthcare a priority. In this region, the primary country-specific markets are Egypt, Saudi Arabia, and UAE, followed by the remaining countries of the MEA region.

Key Players

The key players in the global microbiology testing market include Alere (USA), Beckman Coulter Inc. (USA), Becton Dickinson (BD) (USA), Biomérieux SA (France), Cepheid (USA), F. Hoffmann-La Roche Ltd (Switzerland), and Thermo Fisher Scientific Inc. (USA).

Latest Industry News

Leading small molecule innovator and generic Active Pharmaceutical Ingredients (APIs) manufacturer Cambrex Corporation, who also specialize in finished dosage forms, has acquired Avista Pharma Solutions (“Avista”), a contract development, manufacturing, and testing organization, from Ampersand Capital Partners. Avista is also a microbiology testing leader. 2 JAN 2019
Clear Safety, the flagship product of Clear Labs has received AOAC Performance Tested certification for Salmonella enterica Clear Labs is a unique automated and intelligent next-generation sequencing (NGS) platform purpose-built for food safety testing. Clear Safety combines advanced microbiology, data science, robotic automation, software analytics, and state-of-the-art NGS sequencing, to not only to lower the costs significantly but to also achieve greater than 99.9% accuracy. 4 DEC 2018

Browse Complete 129 Pages Premium Research Report Enabled with 129 Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/microbiology-testing-market-697

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Friday, 8 February 2019

Oncology Information Systems Market Share, Opportunities, Segmentation and Forecast to 2023

Market Scenario

Global oncology information systems (OIS) market is expected to register a healthy CAGR over the forecast period. The market held a market value of USD 2,356.6 million in 2017 and is projected to grow at a CAGR of 7.5% during the forecast period. OIS is a comprehensive information and image management solution that facilitates the management of patient treatment schedules, treatment plans, treatment delivery, and treatment summaries. This system involves the exchange of information between radiation therapy departments and the healthcare enterprises. Factors attributed for the market growth are worldwide growing geriatric population along with rising prevalence of cancer, increasing investments in cancer research, and technological advancements in OIS. The International Agency for Research on Cancer (IARC) stated that there were 14 million new cases of cancer in 2012, that grew to 17.0 million in 2018, which is anticipated to reach to more than 22 million by 2030. Progress in developing treatments is enabling investors to invest in oncology research. Increasing equity investments in cancer-therapeutics startups is foreseen to shape the OIS vertical in the near future. On the contrary, higher costs associated with OIS services are anticipated to restrain the market growth over the forecast period.

Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/7080

Key players

Accuray Incorporated, Cerner Corporation, Philips Healthcare, McKesson Corporation, Altos Solutions, Inc., Elekta AB, Varian Medical Systems, Inc., Flatiron Health, Inc., RaySearch Laboratories, Epic Systems Corporation, Bogardus Medical Systems, Inc., and CureMD Healthcare are some of the prominent players in the global oncology information systems market.

Segmentation

The global oncology information systems market has been segmented into product & service type, application, and end user.

By product & service type, the market has been segmented into software and professional services. The software segment is further categorized into patient information systems and treatment planning systems. The professional services segment is further divided into consulting/optimization services, implementation services, and post-sale & maintenance services. The software for patient information systems segment spearheaded the market in 2017 as these systems offer advantages including planned treatment and remote access due to digital availability as compared to conventional record maintenance methods.

On the basis of application, the market has been classified into medical oncology, radiation oncology, and surgical oncology. The medical oncology segment would lead the market over the forecast period owing to rising applications of OIS in efficiently managing, interpreting, analyzing, and storing the patient information, as well as, in predicting the treatment results for patients, thereby improving their survival rates.

Based on end user, the market has been categorized into hospitals & oncology clinics, government institutes, and research centers.

The global oncology information systems market has been segmented by region into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The oncology information systems market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European oncology information systems market has been segmented into Western Europe and Eastern Europe. The Western Europe oncology information systems market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

The oncology information systems market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The oncology information systems market in the Middle East & Africa has been segmented into the Middle East and Africa.

Regional Market Summary

Geographically, the Americas would grab the highest market share over the forecast period due to the presence of oncology information systems providers, changing lifestyle coupled with rising burden of cancer, increasing expenditure on healthcare, and adoption of oncology information systems in the US and Canada. The IARC reported that in 2018, the Americas have 13.3% of the global population and accounted for 21.0% of incidence and 14.4% of mortality worldwide.

The oncology information systems market in the Middle East & Africa will exhibit considerable market growth rate from 2018 to 2023. Majority of the regional market is likely to govern by the Middle East region due to the presence of world-class cancer treatment centers in Dubai, Saudi Arabia, increasing healthcare sector reforms, and gradually rising investments in OIS sector.

Growing adoption of OIS in European countries, namely, UK, Germany, France, Italy, and Spain, as the major market value contributors such as Philips Healthcare, Elekta AB, and RaySearch Laboratories are headquartered in the region.

Asia-Pacific would represent the phenomenal growth during the forecast period due to growing elderly population coupled with rising prevalence of cancer. The World Health Organization (WHO) and IARC reported that the proportions of cancer deaths in Asia (57.3%) are higher than the proportions of incident cases (48.4%) due to the higher frequency of certain cancer types associated with poorer prognosis and higher mortality rates.

Browse Complete 90 Pages Premium Research Report Enabled with 81 Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/oncology-information-systems-market-7080

Detailed Table Of Contents:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1. Definition

2.2. Scope Of The Study

2.2.1. Research Objective

2.2.2. Assumptions governed

2.2.3. Limitations

Chapter 3. Research Methodology

3.1. Introduction

3.2. Primary Research

3.3. Secondary Research

3.4. Market Size Estimation

Chapter 4. Market Dynamics

4.1. Drivers

4.2. Restraints

4.3. Opportunities

4.4. Challenges

4.5. Macroeconomic Indicators

4.6. Detection Technique Trends & Assessment

Chapter 5. Market Factor Analysis

5.1. Porter’s Five Forces Analysis

5.1.1. Bargaining Power Of Suppliers

5.1.2. Bargaining Power Of Buyers

5.1.3. Threat Of New Entrants

5.1.4. Threat Of Substitutes

5.1.5. Intensity Of Rivalry

…Continued!

Send an Enquiry @ https://www.marketresearchfuture.com/enquiry/7080

About US:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Medical Gases and Equipment Market, Segments, Growth and Value Chain 2018

Market Scenario:

Global Medical Gases And Equipment Market is expected to register a healthy CAGR over the forecast period. The market held a market value of USD 13.0 Billion in 2017 and is projected to grow at a CAGR of 7.5% during the forecast period. Medical gas is manufactured, packaged, and intended for administration to a patient during diagnosis, anesthesia, and therapy. Medical gases are the life-supporting element which gives direct influence in maintaining or saving the patient’s life. Medical gas equipment are the supply systems used by end users to provide or create or distribute medical gases in the piping system. Factors characterizing the market growth are worldwide growing geriatric population coupled with rising prevalence of chronic diseases, the presence of favorable government initiatives such as industry-friendly safety, and rising demand for home healthcare. Geriatric population is highly prone to develop chronic diseases, namely, diabetes, cancer, asthma, respiratory diseases, and cardiovascular diseases. The World Health Organization (WHO) projected worldwide population aged 60 years and above will grow from 962.0 million in 2017 to more than 2.0 billion in 2050 to 3.1 billion by 2100.

Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/6940

Key players:

Atlas Copco, Air Liquide, Praxair Technology, Inc., Airgas, Inc., Messer Group GmbH, AB Matheson Tri-Gas, Inc., The Linde Group, TAIYO NIPPON SANSO CORPORATION, Amico Corporation, SCI Analytical, SOL S.p.A., Rotarex SA, GCE Holding AB, Air Products and Chemicals, Inc., and Matheson Tri-Gas, Inc. are some of the prominent players in the global medical gases and equipment market.
Segmentation:

The Global Medical Gases And Equipment Market has been segmented into product, application, and end user.By product, the market has been segmented into medical gases, medical gas mixtures, and medical gas equipment. The medical gases segment has been further categorized into nitrogen gas, nitrous oxide gas, oxygen gas, carbon dioxide gas, helium gas, and medical air. The medical gases segment spearheaded the market in 2017 owing to worldwide increasing patient hospitalization and a surge in the number of patients suffering from respiratory diseases.The medical gas mixtures segment is further categorized into medical laser gas mixtures, medical drug gas mixtures, sterilant gas mixtures, lung diffusion mixtures, blood gas mixtures, aerobic gas mixtures, anaerobic gas mixtures, and breathing zone monitoring calibration standard. The medical gas equipment is further categorized into air compressors, vacuum systems, flow meters, cylinders, alarm systems, masks, and others (manifolds, regulators, and outlets).

On the basis of application, the market has been segmented into therapeutic applications, diagnostic applications, pharmaceutical manufacturing & research, and others. The therapeutic applications segment is further categorized into respiratory therapies, cardiovascular therapies, anesthesia delivery, and others.Based on end user, the market has been segmented into hospitals & clinics, academic & research institutions, pharmaceutical & biotechnology companies, and home healthcare.The Global Medical Gases And Equipment Market has been segmented by region into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The medical gases and equipment market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European Medical Gases And Equipment Market has been segmented into Western Europe and Eastern Europe. The Western Europe Medical Gases And Equipment Market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.The Medical Gases And Equipment Market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The medical gases and equipment market in the Middle East & Africa has been segmented into the Middle East and Africa.

Regional Market Summary

Geographically, the Americas is expected to dominate the global medical gases and equipment market due to the domicile of key market participants, the presence of sophisticated healthcare infrastructure and target population, and growing elderly population & prevalence of chronic diseases such as diabetes, cancer, asthma, respiratory diseases, cardiovascular diseases, and other non-communicable diseases.Europe is also likely to hold substantial market share over the forecast period owing to the presence of various associations, namely, the MGA (Medical Gas Association) and EIGA (European Industrial Gases Association), and federations such as the European Federation of Precision Mechanical and Optical Industries EUROM.

The market in Asia-Pacific is expected to exhibit the fastest growth during the forecast period attributed to the presence of large population base in countries like China & India, improving healthcare infrastructure coupled with rising spending on healthcare.The medical gases and equipment market in the Middle East & Africa would register the modest market growth rate from 2018 to 2023. Majority of the regional market is anticipated to be governed by the Middle East region due to increasing healthcare sector reforms.

Browse Complete 85 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/medical-gases-and-equipment-market-6940

About US:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Male Breast Cancer Market to Observe Significant Growth by 2018

Market Scenario:

Although breast cancer is common in women, even men suffer from the same. Men also have breast tissues and cancer starts when these tissues start to grow out of control. The breast ducts and glands present in men are not functional, but cancer in these areas can spread when cancer cells enter the blood or lymph system and are carried in the whole body. Men who have suffered from cancer before and undergone radiation therapy are at a high risk of suffering from male breast cancer. The rising geriatric population and an increasingly obese population resulting in high levels of estrogen in males are expected to drive the growth of the market during the forecast period. According to an article published by the National Cancer Institute in April 2018, most of the men who suffer from breast cancer are 60 to 70 years old. Additionally, the rising healthcare expenditure is likely to boost the market growth. On the other hand, lack of knowledge of the disease and high cost of treatment may hinder the growth of the market during the forecast period.

Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/6505

Numerous factors such as increasing obese population and growing geriatric population are expected to drive the growth of the market. For instance, in July 2017, the Bristol-Myers Squibb Company announced a broad clinical collaboration with Clovis Oncology for evaluating the combination of cancer drugs Nivolumab and Rucaparib in Phase 2 and Phase 3 clinical trials in multiple tumor types.

Moreover, favorable healthcare expenditures boost the growth of the market. However, lack of knowledge and the high cost of treatments may hamper the market growth during the assessment period.

The global male breast cancer market is expected to grow slowly at a CAGR of ~ 3.6% during the forecast period from 2018 to 2023. Male breast cancer is caused when the breast tissues of males start growing out of control and become cancerous.

Segmentation

The global male breast cancer market has been segmented into type, diagnosis, and treatment.

The market, on the basis of type, has been segmented into, ductal carcinoma in situ, Paget’s disease of the nipple, inflammatory breast cancer, and infiltrating ductal carcinoma.

The market, by diagnosis, has been segmented into, mammography, biopsy, PET scan, CT scan, MRI scan, and other tests. On the basis of diagnosis, biopsy is anticipated to record the largest growth owing to its accuracy of diagnosing the disease. It is also expected to be the fastest growing segment.

By diagnosis, biopsy is further segmented into, fine needle aspiration biopsy, core biopsy, and excisional biopsy.

The market, by treatment, has been segmented into, local treatments and systemic treatments.

By treatment, local treatments are further segment into, surgery and radiation therapy.

Surgery is further segmented into, mastectomy, breast-conserving surgery, and lymph nodes biopsy.

By treatment, systemic treatments are further segmented into, chemotherapy, hormone therapy, and targeted therapy.

Hormone therapy is further segmented into, using drugs and orchiectomy (castration).

Chemotherapy is further segmented into, adjuvant therapy and neoadjuvant therapy.

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The male breast cancer market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

Targeted therapy is further segmented into, for HER2 positive breast cancer, for hormone receptor-positive breast cancer, and for cancer with BRCA mutations.

The European male breast cancer market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

The male breast cancer market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The male breast cancer market in the Middle East and Africa has been segmented into the Middle East and Africa.

Key players

Achieve Life Sciences, Inc., Pfizer, Eli Lilly and Company, Bristol-Myers Squibb Company, F. Hoffmann-La Roche, Sanofi, Novartis AG, BioNumerik Pharmaceuticals Inc., Seattle Genetics, Inc., GlaxoSmithKline plc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., AstraZeneca, Accord Healthcare, and Bayer AG are some of the key players in the global male breast cancer market.

Regional Market Summary

Geographically, the Americas is anticipated to dominate the global male breast cancer market owing to the changing lifestyle and rising prevalence of breast cancer. According to an article published by, the American Cancer Society in April 2018, the lifetime risk of getting breast cancer in men is approximately 1 in 833. Europe is expected to hold the second largest position in the global male breast cancer market. The market growth in this region is attributed to the growing prevalence of rare cancers, the availability of funds for research, and increasing healthcare expenditure. According to the Cancer Research UK, 371 new cases of male breast cancer were reported in 2015 in the UK.

Asia-Pacific is anticipated to be the fastest growing region in the market due to the rising awareness regarding early symptoms of cancer and government support for healthcare facilities. According to a study published by the European Society for Medical Oncology in January 2016, there were 4.3 million new cases of cancer in China in 2015.

On the other hand, the Middle East and Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle Eastern region due to growing government initiatives for the healthcare sector.

Browse Complete 100 Pages Premium Research Report Enabled with 90 Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/male-breast-cancer-market-6505

About US:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Magnetic Resonance Imaging (MRI) Market Segmentation Detailed Study with Forecast Up To 2018

Magnetic Resonance Imaging (MRI) Market - Scenario:

Magnetic resonance imaging (MRI) systems is a non-invasive technique in which light is used to interrogate cellular and molecular function in the living body by exploiting the special properties of photons. Magnetic resonance imaging (MRI) systems are surpassing the radiology imaging market due to its myriad advantages over it. This market is mainly driven by rising demand for non-invasive procedures, harmful effects of radiation-based imaging, increase in research and development activities in the life sciences sector, and increasing application of magnetic resonance imaging (MRI) systems techniques in drug discovery processes and preclinical research, Moreover factors such as rising geriatric population which leads to increase in cardiovascular, neurological and ophthalmic disorders is also fueling the growth of this market. However, the market growth is restricted by factors such as stringent regulatory approval procedures high costs of instruments, scarcity of skilled operators, and insufficient reimbursements policies for magnetic resonance imaging (MRI) systems procedures.

Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/6194

The Global Magnetic Resonance Imaging (MRI) Systems market is expected to be of value USD 5 Billion in 2023 and to grow at a depict 3.5% CAGR during the forecast period.

Magnetic Resonance Imaging (MRI) Systems Market Key Players:

Hitachi
Siemens AG
Canon Medical Systems
GE Healthcare
Philips
Toshiba Corporation
Toshiba Corporation
Xingaoyi
Aurora Imaging Technologies, Inc.

Market Segmentation:

The global magnetic resonance imaging (MRI) systems market is segmented on the basis of type, field strength, disease application and end user.

Considering the type, the market is segmented into open MRI, closed MRI, standard bore MRI, wide-bore MRI.

On the basis of field strength, the market is segmented into high-field MRI systems, 1.5t MRI systems, 3t MRI systems, low-to-mid-field MRI systems, very-high-field MRI systems, and others.

Based on region the market is segmented into Americas, Europe, Asia Pacific, and the Middle East and Africa. The American region is segmented into North America and South America. Similarly, Europe is segmented into Western Europe and Eastern Europe.

On account of disease application, the market is segmented into the spine and musculoskeletal MRI, brain and neurological MRI, pelvic and abdominal MRI, breast MRI, cardiovascular MRI, and others

According to the end user, the market is segmented into diagnostic imaging centers, hospitals and clinics, research laboratories, and pharmaceutical &biotechnology companies.

Regional Market Summary:

Americas is the market leader and has an attractive market for magnetic resonance imaging (MRI) systems owing to increasing prevalence of cardiovascular, neurological and ophthalmic disorders pertaining to rising geriatric population which is a major trigger factor for this disease. Additionally, factors such as increasing government initiatives and funding for research in medical devices sector, rising demand for accurate diagnosis, awareness about adverse effects of radiation imaging, ability to provide in-depth images of soft tissues and vascular systems and presence of pharmaceutical giants also propel the market growth in this region.

Europe accounts for the second largest market and holds a healthy share in the global magnetic resonance Imaging (MRI) systems market due to major driving factors like availability of advanced treatment facilities, increasing healthcare expenditure, good healthcare infrastructure and flourishing medical device industry due to the presence of major market players. Additionally, knowledge about the benefits of Magnetic Resonance Imaging (MRI) Systems over radiation imaging and capability of inhabitants to afford the diagnostics is spurring the market growth.

Asia Pacific is expected to be the fastest growing market with most promising growth possibilities. According to a report published by the department of neurology in 2014, it is estimated that for the current population of 1.27 billion, approximately 30 million people suffer from neurological disorders in India. Thus, owing to the huge patient pool, a faster adaptation of healthcare technology, government initiatives to increase the healthcare quality, availability favorable insurance policies market growth will be accelerated during the forecast period. Moreover, due to lower cost of clinical trials and research key players have been setting up their regional headquarters and manufacturing plants in Singapore, China, Japan, Korea, and Australia which make a positive growth curve in Magnetic Resonance Imaging (MRI) Systems market in future.

The Middle East & Africa is expected to show the least growth in the market due to some major factors such as lack of awareness, limited access and availability of treatment facilities. In the Middle East, the United Arab Emirates and Saudi Arabia is the largest market share owing to the development of healthcare industry and rising availability of specialty care centers. But the market might show steady growth due to and government initiatives to improve quality of healthcare in this region.

Browse Complete 100 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/magnetic-resonance-imaging-market-6194

About US:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Immune Thrombocytopenia (ITP) Market Growth and Restrain Factors Analysis By 2023

Market Scenario:

The Global Market for Immune Thrombocytopenia is projected to surpass a valuation of USD 2,300 Mn by 2023, reflecting a compound annual growth rate of 5.78% between 2018 and 2023. Rising prevalence of immune thrombocytopenia (ITP) worldwide has fueled the demand for ITP therapeutics. Increased government effort to improve healthcare infrastructure in countries such as India, China and Brazil has reflected favorably on the global ITP market. In addition, increased focus on development of novel drugs and therapeutics is also having a positive impact on the market. Autoimmune diseases, chronic infections, medications, pregnancy, and certain cancers are common secondary triggers of ITP.

Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/6996

The MRFR report includes a thorough assessment of the global immune thrombocytopenia (ITP) market along with a five-year (2018-2023) revenue forecast. The report includes a discussion on several key market elements. The scope of the discussion also covers different ITP treatments that are currently available such as intravenous immunoglobulins, thrombopoietin receptor agonists and corticosteroids among other. It also covers revenue analysis of major end-users of immune thrombocytopenia, which covers hospitals and clinics, specialty centers, and research and academic institutes. A detail analysis of the various sub-markets across key region of the world is also available in the report.

Historical market trends, market dynamics, forecast, market value by region as well as by segmentation, country-level analysis for each market segment, key player’s market share analysis and market factor analysis which covers supply chain and Porter’s five forces analysis of the market

Companies Covered:

CSL Limited, Amgen Inc., F.Hoffmann-La Roche Ltd., Kyowa Hakko Kirin Co., Ltd., Rigel Pharmaceuticals, Inc., Shionogi Inc., Dova Pharmaceuticals, Novartis AG, Jiangsu Hengrui Pharmaceutical Co., Ltd., Shire and Ligand Pharmaceuticals, Inc.

Research Methodology:

The research methodology envelops the range and depth of markets and industries that ensures the best outlooks are presented. The methodology successfully combines primary and secondary research methods to present exclusive and pertinent content that can aid in well-versed decision making. The different advances in markets are uniquely included in the reports by employing top-down and bottom-up approaches. Insightful data, advantageous scenarios, and outline of the emerging markets make for a complete and astute guide into the beat of the market. Also, the consistency levels of our reports offer our users adept intelligence that can shape the base of strategies they devise to gain the preferred market portions and hold & enhance their current customer base in several geographies.

Browse Complete 85 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/immune-thrombocytopenia-itp-market-6996

About US:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Heart Tumor Market Dynamics, Forecast, Analysis and Supply Demand 2018

Heart Tumor Market Scenario

Cardiac tumors is a rare disease that aredifficult to diagnose. They are divided on the basis of type into primary and secondary tumors. The prevalance of the secondary tumors is higher than the primary tumors. Majority of the primary cardiac tumors are benign in origin. The high incidences of metastatic tumors is attributed to various types of cancers such as lung, breast, renal cancer, lymphomas and melanomas. Clinical manifestations of these tumors generally based on the size and location of the tumors and spread to the adjacent tissues rather than the type of the tumor itself. Echocardiography is the major tool used for diagnosis of the tumors. Other imaging modalities include cardiac MRI, cardiac CT, and 3D echocardiography, which may offer some additional information with histological examination.

Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/5065

According to the surgery and autopsy reports, primary cardiac tumors are rare with an incidence rate of about 0.3%-0.7%. Malignant primary cardiac sarcomas are usually located in the right atrium of the heart and are most commonly angiosarcomas. The malignant primary cardiac tumors are often diagnosed in young patientswho have a poor prognosis and survival rate of only 10% According to the WHO, the prevalence of melanoma skin cancers has been increasing from the past few decades. Furthermore, 132,000 melanoma skin cancers cases are reported each year across the globe.
A small percentage of cardiac tumor cases are hereditary, the tumors can also be associated with another health condition, such as LAMB Syndrome, Carney Syndrome or NAME Syndrome. However, most often, the tumor develops without being associated with any health condition or presence of a family history. They result from cell overgrowth but mostly cardiac tumors results from metastatic condition, where cells from other cancerous organ such as lung and breast, soft-tissues and metastasizes to the heart.

The Global Heart Tumor Market is expected to grow at a CAGR of approximately 7.1% during the forecast period 2017-2023.

Heart Tumor Market Key Players

Some of key the players in the Global heart tumor market are Tomtec Imaging Systems GmBh, Koninklijke Philips N.V., Siemens Healthineers, Circle Cardiovascular Imaging Inc., Toshiba Corporation, Shimadzu Corporation, CardioComm Solutions Inc., Integer Holdings Corporation, Pie Medical Imaging, HeartSciences, 3mensio Medical Imaging, and eMedica, S.L.

Heart Tumor Market Segmentation

The heart tumor is segmented on the basis of type, diagnosis, treatment.

On the basis of the type, the market is segmented into primary tumors and secondary tumors. The primary tumors are divided into benign and malignant. The benign tumors is further categorized into myxoma, papillary heart tumors, fibromas, rhabdomyomas, angioma, and lipomas. The malignant tumors are divided into rhabdomyosarcoma, mesenchymomas, neurosarcoma, fusiform cell tumors, malignant heart hemangioma, and lymphosarcoma. The secondary tumor is categorized into metastatic and contiguity. The metastatic secondary tumors are divided into hematogenic and lymphatic and the contiguity is sub categorized into mediastinal tumors, lung tumors and oesophageal, or cardia tumor.

On the basis of the diagnosis, the market is classified into echocardiogram, Computed Tomography (CT) scan, Magnetic Resonance Imaging (MRI), radionuclide imaging, Position Emission Tomography (PET) Scan, myocardial biopsy, cardiac catherization, and electrophysiology test.

On the basis of the treatment, the market is classified into surgery, chemotherapy, radiation therapy. Furthermore, the surgery is further categorized into open heart surgery, minimal invasive surgery, and heart transplant surgery

International Heart Tumor Market Regional Analysis

The global heart tumor market consists of four major regions: the Americas, Europe, Asia Pacific, and the Middle East and Africa. The Americas dominate the market owing to the rising awareness among people and increasing healthcare expenditure. The type of tumors also aids in selection of treatment procedure. For instance, in patient with heart cancers, the results of cardiac imaging could be used to see if the the tumor is spread to the adjacent tissues, which can be further used to remove the portion by performing excision surgery or pursuing treatment with medications.

Apply for Exclusive Discount @ https://www.marketresearchfuture.com/check-discount/5065

The growing demand for outpatient surgeries and increasing preference of specialized cardiac imaging devices are some of the major factors intended to cost-effective technology, which further drives the demand for heart tumor treatment in the European region.
Increasing prevalence of metastatic tumors, which require surgical procedures and growing medical tourism in Asia Pacific region are favoring the growth of this market. According to the WHO estimate, 75% of the cardiovascular diseases occur are in low and middle income regions including Asia Pacific and the Middle East and Africa regions.

About US:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com